The antisense & RNAi therapeutics market consists of sales of antisense & RNAi therapeutics products and related services by entities (organizations, sole traders and partnerships) that develop antisense & RNAi therapeutics to treat various diseases. RNA interference (RNAi)-based and RNA-based antisense oligonucleotide therapies are advanced methods used for the treatment of various respiratory diseases including chronic obstructive pulmonary disease (COPD) and asthma. In addition to this, antisense & RNAi therapeutics finds its application in curing cancer, infectious diseases, cardiovascular diseases, and genetic disorders.
Antisense & RNAi Therapeutics Market Report Segments:
1) By Technology: RNA Interference, Antisense RNA
2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-Dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods
3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other
Read More On The Global Antisense & RNAi Therapeutics Market Report:
Antisense & RNAi Therapeutics Market Size Forecast:
The global antisense & RNAi therapeutics market is expected to grow from $1.11 billion in 2020 to $1.2 billion in 2021 at a compound annual growth rate (CAGR) of 8.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $1.79 billion in 2025 at a CAGR of 11%.
Major Players in the Antisense & RNAi Therapeutics Market:
The major players covered in the global antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline Plc, Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics, Antisense Therapeutics Ltd., Arbutus Biopharma (formerly known as Tekmira Pharmaceuticals), Bio-Path Holdings Inc., Calando Pharmaceuticals, Dicerna Pharmaceuticals, Enzon Pharmaceuticals Inc, Gradalis, iCo Therapeutics, miRagen Therapeutics, Olix Pharmaceuticals, OncoGeneX Pharmaceuticals, Lorus Therapeutics (Aptose Biosciences), Regulus Therapeutics, Rexahn Pharmaceuticals, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Silence Therapeutics Plc, Sirnaomics Inc., Tekmira Pharmaceuticals, Cenix BioScience, Sirnaomics.
Request For A Sample:
Antisense & RNAi Therapeutics Global Market Report 2021 is one of a series of new reports from The Business Research Company that provide market overviews, analyze and forecast market size and growth for the whole market, segments and geographies, trends, drivers, restraints, leading competitors revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies. The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors approaches.
Here Is A List Of Similar Reports By The Business Research Company:
Oncology Drugs Market
Ophthalmology Drugs Market
Dry Eye Medication Market
Interested to know more about The Business Research Company?
Read more about us at
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293